Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Centrum Neurologii Krzysztof Selmaj

Verified siteinfoFast reply

Poland ul. Tylna 12, 90-324 Lodz, Poland

  • 5 trials recruiting
  • Relapsing multiple sclerosis · Multiple sclerosis · Chronic inflammatory demyelinating polyradiculoneuropathy
  • Adult patients

About Specializations

Centrum Neurologii Krzysztof Selmaj in Lodz, Poland specialises in clinical trials of conditions such as Relapsing multiple sclerosis, Multiple sclerosis, Chronic inflammatory demyelinating polyradiculoneuropathy, Multiple sclerosis relapse, and other specialisations. This site conducts important research.

Main research areas of the site

Neurology

The medical center is at the forefront of neurological research, with a particular focus on relapsing multiple sclerosis (RMS). The institution is dedicated to advancing the understanding and treatment of this complex condition through innovative research and clinical trials.

  • Relapsing Multiple Sclerosis (RMS)
  • Long-term Safety and Tolerability Studies
  • Advanced Therapeutic Interventions

By conducting extensive studies on the long-term safety and tolerability of treatments like ofatumumab, the center contributes significantly to the development of effective therapies that improve patient outcomes and quality of life.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
ul. Tylna 1290-324 LodzPoland
Open in maps ↗
Recruiting now
5 trials
Conditions studied
8
Partner status
Verified site

More sites in LodzPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

17 clinical trials

Relapsing multiple sclerosis

Recruiting

A study to evaluate the safety and how the body uses ublituximab injections in patients with multiple sclerosis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ublituximab
  • Sponsor:Tg Therapeutics Inc.

Relapsing multiple sclerosis

Recruiting

Study on the Effectiveness of Ublituximab and Drug Combination for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cetirizine
  • Sponsor:Tg Therapeutics Inc.

Multiple sclerosis

Recruiting

Safety and Feasibility of Home Use On-Body Injection System for Subcutaneous Ocrelizumab in Adults with Multiple Sclerosis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Study of DNTH103 Treatment for Adults with Chronic Inflammatory Demyelinating Polyneuropathy: Comparing Effectiveness with Placebo

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:DNTH103
  • Sponsor:Dianthus Therapeutics Inc.

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Study on Long-term Safety and Efficacy of Efgartigimod PH20 SC in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Multiple sclerosis+1

Not recruiting

Study on the Effectiveness and Safety of Ocrelizumab for Patients with Progressive Multiple Sclerosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Relapsing multiple sclerosis

Not recruiting

Study on Ublituximab for Patients with Relapsing Multiple Sclerosis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ublituximab
  • Sponsor:Tg Therapeutics Inc.

Relapsing multiple sclerosis

Not recruiting

Phase III Study of the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Fenebrutinib
  • Sponsor:F. Hoffmann-La Roche AG

Multiple sclerosis

Not recruiting

A Study Comparing Two Forms of Ocrelizumab Given Under the Skin in Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Relapsing-remitting multiple sclerosis

Not recruiting

Study Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Amgen Inc.

Relapsing multiple sclerosis

Not recruiting

Study on Fenebrutinib and Teriflunomide for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Fenebrutinib
  • Sponsor:F. Hoffmann-La Roche AG

Multiple sclerosis relapse

Not recruiting

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.